HaematologyOncology
Tumour Lysis Syndrome
Tumour Lysis Syndrome clinical pathway.
Source: Cairo-Bishop; BSH; NICE — Best Practice
Step 1 of ~3
info
Risk Assessment
Risk Assessment
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Rasburicase · Tumour Lysis Syndrome
- Methylene Blue · Guanylate Cyclase / Nitric Oxide Pathway Inhibitor
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- Sodium phenylbutyrate · Ammonia scavenger (alternative pathway)
- Pramipexole (Restless Legs Syndrome — Elderly) · Dopamine Agonist (D2/D3 Receptor)
- Marstacimab · Anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
- Anticoagulation Reversal · BSH 2016 / ESC
Decision support only. Always apply local guidelines and clinical judgement.